294 related articles for article (PubMed ID: 17803522)
1. Inverse agonist exposure enhances ligand binding and G protein activation of the human MT1 melatonin receptor, but leads to receptor down-regulation.
Kokkola T; Vaittinen M; Laitinen JT
J Pineal Res; 2007 Oct; 43(3):255-62. PubMed ID: 17803522
[TBL] [Abstract][Full Text] [Related]
2. Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells.
Witt-Enderby PA; Dubocovich ML
Mol Pharmacol; 1996 Jul; 50(1):166-74. PubMed ID: 8700109
[TBL] [Abstract][Full Text] [Related]
3. Modulation of melatonin receptors and G-protein function by microtubules.
Jarzynka MJ; Passey DK; Ignatius PF; Melan MA; Radio NM; Jockers R; Rasenick MM; Brydon L; Witt-Enderby PA
J Pineal Res; 2006 Nov; 41(4):324-36. PubMed ID: 17014689
[TBL] [Abstract][Full Text] [Related]
4. The functional role of cysteines adjacent to the NRY motif of the human MT1 melatonin receptor.
Kokkola T; Salo OM; Poso A; Laitinen JT
J Pineal Res; 2005 Aug; 39(1):1-11. PubMed ID: 15978051
[TBL] [Abstract][Full Text] [Related]
5. Knock-down of RGS4 and beta tubulin in CHO cells expressing the human MT1 melatonin receptor prevents melatonin-induced receptor desensitization.
Witt-Enderby PA; Jarzynka MJ; Krawitt BJ; Melan MA
Life Sci; 2004 Oct; 75(22):2703-15. PubMed ID: 15369705
[TBL] [Abstract][Full Text] [Related]
6. MT1 melatonin receptor internalization underlies melatonin-induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation.
Bondi CD; McKeon RM; Bennett JM; Ignatius PF; Brydon L; Jockers R; Melan MA; Witt-Enderby PA
J Pineal Res; 2008 Apr; 44(3):288-98. PubMed ID: 18339124
[TBL] [Abstract][Full Text] [Related]
7. Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists.
Nonno R; Pannacci M; Lucini V; Angeloni D; Fraschini F; Stankov BM
Br J Pharmacol; 1999 Jul; 127(5):1288-94. PubMed ID: 10455277
[TBL] [Abstract][Full Text] [Related]
8. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells.
Girgert R; Hanf V; Emons G; Gründker C
J Pineal Res; 2009 Aug; 47(1):23-31. PubMed ID: 19522736
[TBL] [Abstract][Full Text] [Related]
9. Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells.
Imbesi M; Uz T; Manev H
Neuroscience; 2008 Sep; 155(4):1160-4. PubMed ID: 18664376
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells.
Nonno R; Lucini V; Pannacci M; Mazzucchelli C; Angeloni D; Fraschini F; Stankov BM
Br J Pharmacol; 1998 Jun; 124(3):485-92. PubMed ID: 9647472
[TBL] [Abstract][Full Text] [Related]
11. Delta opioid receptor down-regulation is independent of functional G protein yet is dependent on agonist efficacy.
Remmers AE; Clark MJ; Liu XY; Medzihradsky F
J Pharmacol Exp Ther; 1998 Nov; 287(2):625-32. PubMed ID: 9808689
[TBL] [Abstract][Full Text] [Related]
12. 17Beta-estradiol modulates hMT1 melatonin receptor function.
Masana MI; Soares JM; Dubocovich ML
Neuroendocrinology; 2005; 81(2):87-95. PubMed ID: 15809517
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5'-O-(gamma-thiotriphosphate) binding in rat striatal membranes.
Odagaki Y; Toyoshima R
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1304-12. PubMed ID: 16824659
[TBL] [Abstract][Full Text] [Related]
15. Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor.
Carbajo-Pescador S; García-Palomo A; Martín-Renedo J; Piva M; González-Gallego J; Mauriz JL
J Pineal Res; 2011 Nov; 51(4):463-71. PubMed ID: 21718361
[TBL] [Abstract][Full Text] [Related]
16. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.
Bruins Slot LA; Palmier C; Tardif S; Cussac D
Neuropharmacology; 2007 Aug; 53(2):232-41. PubMed ID: 17588617
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterisation of melatonin mt1 receptor-mediated stimulation of [35S]-GTPgammaS binding.
Beresford IJ; Harvey FJ; Hall DA; Giles H
Biochem Pharmacol; 1998 Nov; 56(9):1167-74. PubMed ID: 9802327
[TBL] [Abstract][Full Text] [Related]
18. 2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists.
Spadoni G; Balsamini C; Bedini A; Diamantini G; Di Giacomo B; Tontini A; Tarzia G; Mor M; Plazzi PV; Rivara S; Nonno R; Pannacci M; Lucini V; Fraschini F; Stankov BM
J Med Chem; 1998 Sep; 41(19):3624-34. PubMed ID: 9733487
[TBL] [Abstract][Full Text] [Related]
19. The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system.
Uz T; Arslan AD; Kurtuncu M; Imbesi M; Akhisaroglu M; Dwivedi Y; Pandey GN; Manev H
Brain Res Mol Brain Res; 2005 May; 136(1-2):45-53. PubMed ID: 15893586
[TBL] [Abstract][Full Text] [Related]
20. Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines.
Lai L; Yuan L; Cheng Q; Dong C; Mao L; Hill SM
Breast Cancer Res Treat; 2009 Nov; 118(2):293-305. PubMed ID: 18979234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
